Research
Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews
BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g6501 (Published 21 November 2014) Cite this as: BMJ 2014;349:g6501
Data supplement
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Figure showing examples of specification of harm outcomes in systematic reviews
- Data Supplement - Table showing examples of specification of harm outcomes in systematic reviews
- Data Supplement - Table showing examples of study classifications for harm outcomes
Related articles
- Editorial Published: 21 November 2014; BMJ 349 doi:10.1136/bmj.g6819
- Research Published: 14 March 2018; BMJ 360 doi:10.1136/bmj.k793
- Research Methods & Reporting Published: 28 September 2018; BMJ 362 doi:10.1136/bmj.k3802
- Analysis Published: 16 October 2019; BMJ 367 doi:10.1136/bmj.l5674
- Research Published: 10 May 2022; BMJ 377 doi:10.1136/bmj-2021-069155
See more
- Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysisBMJ December 05, 2016, 355 i6188; DOI: https://doi.org/10.1136/bmj.i6188
- NHS to fund large trial of pre-exposure prophylaxis for HIV preventionBMJ December 05, 2016, 355 i6537; DOI: https://doi.org/10.1136/bmj.i6537
- Bill to boost medical research funding and speed drug approval passes US houseBMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498
- Alpha blockers for treatment of ureteric stones: systematic review and meta-analysisBMJ December 01, 2016, 355 i6112; DOI: https://doi.org/10.1136/bmj.i6112
- Sixty seconds on . . . solanezumabBMJ November 29, 2016, 355 i6389; DOI: https://doi.org/10.1136/bmj.i6389
Cited by...
- Toxicities of PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Evidence-based medicine and COVID-19: what to believe and when to change
- Adverse effects information in clinical guidelines on pharmacological treatment of depression in children and adolescents: a systematic review
- Outcome reporting bias in Cochrane systematic reviews: a cross-sectional analysis
- Statins for primary prevention of cardiovascular disease
- Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials
- Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look
- Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews
- Tools for assessing risk of reporting biases in studies and syntheses of studies: a systematic review
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer
- Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association
- Inconsistent Reporting Between Meta-analysis Protocol and Publication - A Cross-Sectional Study
- Evidence based medicine manifesto for better healthcare: A response to systematic bias, wastage, error and fraud in research underpinning patient care
- Update on Pediatric Overuse
- Report on a pilot project to introduce a publications officer
- What's in a name? The challenge of describing interventions in systematic reviews: analysis of a random sample of reviews of non-pharmacological stroke interventions
- Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study
- Reporting of harms in systematic reviews and their primary studies